These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29110089)

  • 1. Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
    Takeyama H; Beppu T; Higashi T; Kaida T; Arima K; Taki K; Imai K; Nitta H; Hayashi H; Nakagawa S; Okabe H; Hashimoto D; Chikamoto A; Ishiko T; Tanaka M; Sasaki Y; Baba H
    Surg Today; 2018 Apr; 48(4):431-438. PubMed ID: 29110089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
    Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Tanaka K; Shimada M; Kudo M
    Oncology; 2014; 87 Suppl 1():104-9. PubMed ID: 25427741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Lim S; Han J; Kim GM; Han KH; Choi HJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
    Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
    Shinoda M; Kishida N; Itano O; Ei S; Ueno A; Kitago M; Abe Y; Hibi T; Yagi H; Masugi Y; Tanabe M; Aiura K; Sakamaoto M; Tanimoto A; Kitagawa Y
    World J Surg Oncol; 2015 Apr; 13():144. PubMed ID: 25889667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
    Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
    Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
    Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
    Antoniou EA; Margonis GA; Amini N; Anastasiou M; Angelou A; Kim Y; Kouraklis G
    J BUON; 2016; 21(5):1189-1194. PubMed ID: 27837622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
    Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
    Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
    Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
    Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
    World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Kang MK; Park JG; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Katano Y; Hirooka Y; Ishikawa T; Nakano I; Goto H
    PLoS One; 2015; 10(9):e0138776. PubMed ID: 26421430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.